Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17815
Corporate User License Price USD 750
Corporate User License Price INR 53445
Site License Price USD 500
Site License Price INR 35630
Request a Quote

Report Title

Puma Biotechnology Inc (PBYI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Puma Biotechnology Inc (PBYI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Puma Biotechnology Inc (PBYI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Puma Biotechnology Inc (PBYI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

Puma Biotechnology Inc (Puma) is a biopharmaceutical company that develops novel therapeutics for the treatment of cancer. The company develops and commercializes three drug candidates, namely, PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Its pipeline portfolio also encompasses investigational candidates for various indications such as adjuvant breast cancer, gastric cancer, metastatic breast cancer, and HER2-positive breast cancer, among others. Puma in-licenses its drug candidates and advances its development through clinical testing and for commercial use. Puma is headquartered in Los Angeles, California, the US.

Puma Biotechnology Inc (PBYI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Puma Biotechnology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Celcuity Enters into Agreement with Puma Biotechnology and West Cancer Center 12

Puma Biotechnology and Strata Oncology Enter into Collaboration Agreement 13

Champions Oncology Enters into Agreement with NSABP Foundation and Puma Biotechnology 14

Daiichi Sankyo and Puma Biotech Enter into Research Agreement with Memorial Sloan Kettering Cancer Center 15

Licensing Agreements 16

Pint Pharma Enters into Licensing Agreement with Puma Biotech 16

Medison Pharma Enters into Licensing Agreement with Puma Biotechnology 17

CANbridge Life Sciences Enters into Licensing Agreement with Puma Biotechnology 18

Puma Biotechnology Enters into Licensing Agreement with Specialised Therapeutics 19

Equity Offering 20

Puma Biotech Raises USD172.5 Million in Public Offering of Shares 20

Puma Biotech Raises USD218.5 Million in Public Offering of Shares 22

Puma Biotech Completes Public Offering Of Shares For USD 138 Million 24

Puma Biotech Completes Public Offering Of Common Stock For USD 138 Million 25

Puma Biotechnology Inc-Key Competitors 27

Puma Biotechnology Inc-Key Employees 28

Puma Biotechnology Inc-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Financial Announcements 30

Aug 09, 2018: Puma Biotechnology reports second quarter 2018 financial results 30

May 09, 2018: Puma Biotechnology Reports First Quarter 2018 Financial Results 32

Mar 01, 2018: Puma Biotechnology Announces Fourth Quarter and Full Year 2017 Financial Results 34

Nov 09, 2017: Puma Biotechnology Reports Third Quarter 2017 Financial Results 37

Aug 09, 2017: Puma Biotechnology Reports Second Quarter 2017 Financial Results 38

May 10, 2017: Puma Biotechnology Reports First Quarter 2017 Financial Results 40

Mar 01, 2017: Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results 42

Corporate Communications 44

Dec 14, 2017: Puma Biotechnology Added to NASDAQ Biotechnology Index 44

Product News 45

12/13/2017: Puma Biotechnology Announces Meeting of Scientific Advisory Group on Oncology in Europe to Review Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 45

11/02/2017: Puma Biotechnology Secures USD 100 Million Term Loan from Silicon Valley Bank and Oxford Finance 46

09/04/2018: European Commission grants marketing authorisation for Puma Biotechnology's NERLYNX (neratinib) for extended adjuvant treatment of hormone receptor positive HER2-positive early stage breast cancer 47

08/03/2017: Investigators match novel cancer mutations with potential therapies 48

07/31/2017: Puma Announces Availability of NERLYNX (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in the United States 49

07/21/2017: NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting 50

07/17/2017: FDA approves new treatment to reduce the risk of breast cancer returning 51

07/17/2017: U.S. Food and Drug Administration Approves Puma's NERLYNX (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 52

06/29/2018: Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval of NERLYNX for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 53

06/26/2018: Puma Biotechnology Announces Results of CHMP Reexamination of MAA for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 54

06/02/2018: Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting 55

04/17/2017: Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 56

04/12/2017: Caligor to Support Puma Biotechnology's Expanded Access Program for PB272 (Neratinib) in the United States 57

04/05/2018: Specialised Therapeutics Asia Initiates Early Access Program For Neratinib 58

04/02/2018: NCCN Guidelines for Central Nervous System Cancers Include NERLYNX (neratinib) in Combination with Capecitabine or Paclitaxel as Treatment Options for Patients with Breast Cancer Brain Metastases 59

04/02/2017: Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancer 60

04/02/2017: Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting 61

03/23/2018: Puma Biotechnology Requests Re-examination of Recommendation on Nerlynx 62

02/23/2018: Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 63

Product Approvals 64

Jul 31, 2018: Puma Biotechnology Files New Drug Submission for NERLYNX in Canada 64

Jan 23, 2018: Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 65

Aug 02, 2017: Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP) 66

May 24, 2017: Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib 67

May 22, 2017: Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting 68

Clinical Trials 69

May 24, 2018: Researchers awarded multiple Department of Defense grants in next frontier of breast cancer genomics 69

Jan 31, 2018: Puma Biotechnology Announces Publication of Results from Phase II SUMMIT 'Basket' Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancer 71

Dec 06, 2017: Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium 72

Nov 13, 2017: Puma Biotechnology's 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology 74

Sep 12, 2017: US Oncology Research Plays an Important Role in the Clinical Development for NERLYNX Tablets 75

Sep 08, 2017: Puma Biotechnology Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO 2017 Congress 76

Aug 30, 2017: Puma Biotechnology Announces Publication of Abstracts for ESMO 2017 78

Jul 06, 2017: Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial 79

Jun 03, 2017: Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting 80

May 17, 2017: Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual Meeting 81

Apr 04, 2017: Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting 82

Apr 02, 2017: Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting 84

Mar 01, 2017: Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017 85

Jan 06, 2017: Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients 86

Appendix 87

Methodology 87

About GlobalData 87

Contact Us 87

Disclaimer 87

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

List of Tables

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Puma Biotechnology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Puma Biotechnology Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Celcuity Enters into Agreement with Puma Biotechnology and West Cancer Center 12

Puma Biotechnology and Strata Oncology Enter into Collaboration Agreement 13

Champions Oncology Enters into Agreement with NSABP Foundation and Puma Biotechnology 14

Daiichi Sankyo and Puma Biotech Enter into Research Agreement with Memorial Sloan Kettering Cancer Center 15

Pint Pharma Enters into Licensing Agreement with Puma Biotech 16

Medison Pharma Enters into Licensing Agreement with Puma Biotechnology 17

CANbridge Life Sciences Enters into Licensing Agreement with Puma Biotechnology 18

Puma Biotechnology Enters into Licensing Agreement with Specialised Therapeutics 19

Puma Biotech Raises USD172.5 Million in Public Offering of Shares 20

Puma Biotech Raises USD218.5 Million in Public Offering of Shares 22

Puma Biotech Completes Public Offering Of Shares For USD 138 Million 24

Puma Biotech Completes Public Offering Of Common Stock For USD 138 Million 25

Puma Biotechnology Inc, Key Competitors 27

Puma Biotechnology Inc, Key Employees 28

Puma Biotechnology Inc, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Puma Biotechnology Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person